INTERVIEW: OncoMed CEO Hastings on milestones ahead
This article was originally published in Scrip
Executive Summary
OncoMed Pharmaceuticals has no imminent plans to finance its soon-to-be seven-asset clinical pipeline by selling stock, because the cancer therapy developer's partnerships are structured in a way that "keeps us from having to raise money, which is a corporate goal for the company," chairman and CEO Paul Hastings told Scrip.
You may also be interested in...
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.